Extension of a predictive substrate model for human cytochrome P4502D6.

1. Metoprolol, indoramine, codeine, tamoxifen and prodipine, compounds which are clinically used, and MDMA (ecstasy) were fitted in a small molecule model for substrates of human cytochrome P4502D6. 2. For both the R- and S-enantiomer of metoprolol, the R- and S-enantiomer of MDMA, and for indoramine and codeine (all proven substrates of cytochrome P4502D6) an acceptable fit in the substrate model was obtained. 3. For tamoxifen, for which the involvement of cytochrome P4502D6 in the 4-hydroxylation is uncertain, no acceptable fit could be obtained in the substrate model. 4. For prodipine, a competitive inhibitor of P4502D6, for which the involvement of P4502D6 in the metabolism is uncertain, no acceptable fit in the substrate model could be obtained. 5. The substrate model was extended in a direction in which two large known substrates extend from the original substrate model. This extension did not change the flat hydrophobic region of the original substrate model.

[1]  A. Doig,et al.  Toward the semiquantitative estimation of binding constants guides for peptide peptide binding in aqueous solution , 1991 .

[2]  S. H. Vosko,et al.  Accurate spin-dependent electron liquid correlation energies for local spin density calculations: a critical analysis , 1980 .

[3]  K. Korzekwa,et al.  Predicting the cytochrome P450 mediated metabolism of xenobiotics. , 1993, Pharmacogenetics.

[4]  G. Tucker,et al.  Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol. , 1996, The Biochemical journal.

[5]  A. Parkinson,et al.  Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[6]  H K Kroemer,et al.  "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. , 1995, Life sciences.

[7]  G. Tucker,et al.  Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[8]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[9]  R. Chenery,et al.  Cytochrome P450 maintenance and diazepam metabolism in cultured rat hepatocytes. , 1991, Biochemical pharmacology.

[10]  W U Primrose,et al.  A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding. , 1996, Biochemistry.

[11]  M. Eichelbaum,et al.  Codeine O-demethylation: rat strain differences and the effects of inhibitors. , 1991, Biochemical pharmacology.

[12]  T. Poulos,et al.  Modeling protein-substrate interactions in the heme domain of cytochrome P450(BM-3). , 1994, Acta crystallographica. Section D, Biological crystallography.

[13]  J. Styles,et al.  Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. , 1994, Carcinogenesis.

[14]  T. Leemann,et al.  Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). , 1988, Biochemical and biophysical research communications.

[15]  J. Idle,et al.  The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. , 1994, Pharmacogenetics.

[16]  N. Vermeulen,et al.  A refined substrate model for human cytochrome P450 2D6. , 1997, Chemical research in toxicology.

[17]  F. Guengerich,et al.  Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.

[18]  M. Eichelbaum,et al.  Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism. , 1994, The Journal of pharmacology and experimental therapeutics.

[19]  C Skoda,et al.  The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  U. Meyer,et al.  Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. , 1988, Biochemical pharmacology.

[21]  A. Becke,et al.  Density-functional exchange-energy approximation with correct asymptotic behavior. , 1988, Physical review. A, General physics.

[22]  P. Andrews,et al.  Functional group contributions to drug-receptor interactions. , 1984, Journal of medicinal chemistry.

[23]  G. Tucker,et al.  The metabolism of tamoxifen by human liver microsomes is not mediated by cytochrome P450IID6. , 1991, Biochemical pharmacology.

[24]  A. S. Gross,et al.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. , 1990, Pharmacology & therapeutics.

[25]  D. Lewis.  Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  S A van Acker,et al.  A predictive model for substrates of cytochrome P450-debrisoquine (2D6). , 1992, Chemical research in toxicology.

[27]  F. Guengerich,et al.  Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. , 1985, Cancer research.

[28]  G. Tucker,et al.  Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. , 1997, Biochemical pharmacology.

[29]  N. Vermeulen,et al.  Oxygen and xenobiotic reductase activities of cytochrome P450. , 1995, Critical reviews in toxicology.

[30]  L. Koymans,et al.  Cytochromes P450: their active-site structure and mechanism of oxidation. , 1993, Drug metabolism reviews.

[31]  M J Sternberg,et al.  A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. , 1991, Carcinogenesis.

[32]  D. Lewis,et al.  The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interactions: potential importance to its proposed anti-carcinogenic/carcinogenic actions. , 1996, Carcinogenesis.

[33]  J. Perdew,et al.  Density-functional approximation for the correlation energy of the inhomogeneous electron gas. , 1986, Physical review. B, Condensed matter.

[34]  D. Kupfer,et al.  Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. , 1991, Cancer research.

[35]  R. Parr.  Density-functional theory of atoms and molecules , 1989 .

[36]  W. L. Nelson,et al.  Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[37]  S Jaruratanasirikul,et al.  The inhibitory effect of amiodarone and desethylamiodarone on dextromethorphan O‐demethylation in human and rat liver microsomes , 1994, The Journal of pharmacy and pharmacology.

[38]  J Deisenhofer,et al.  Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. , 1993, Science.

[39]  J Deisenhofer,et al.  Crystal structure and refinement of cytochrome P450terp at 2.3 A resolution. , 1994, Journal of molecular biology.

[40]  Nico P. E. Vermeulen,et al.  A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building , 1993, J. Comput. Aided Mol. Des..

[41]  B C Finzel,et al.  The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450. , 1985, The Journal of biological chemistry.

[42]  G. Screaton,et al.  Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse , 1992, The Lancet.

[43]  C. Wolf,et al.  Species differences in the covalent binding of [14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. , 1995, Biochemical pharmacology.

[44]  J. G. Snijders,et al.  Parallellisation of the Amsterdam Density Functional Programme , 1995 .

[45]  G. Tucker,et al.  The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). , 1994, Biochemical pharmacology.

[46]  R. Skoda,et al.  The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. , 1990, Pharmacology & therapeutics.

[47]  N. Vermeulen,et al.  A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. , 1996, Chemical research in toxicology.